118 related articles for article (PubMed ID: 657590)
1. Production of the complement cleavage product, C3a, by activated macrophages and its tumorolytic effects.
Ferluga J; Schorlemmer HU; Baptista LC; Allison AC
Clin Exp Immunol; 1978 Mar; 31(3):512-7. PubMed ID: 657590
[TBL] [Abstract][Full Text] [Related]
2. Effects of activated complement components on enzyme secretion by macrophages.
Schorlemmer HU; Allison AC
Immunology; 1976 Nov; 31(5):781-8. PubMed ID: 992710
[TBL] [Abstract][Full Text] [Related]
3. Macrophage secretion and the complement cleavage product C3a in the pathogenesis of infections by mycoplasmas and L-forms of bacteria and in immunity to these organisms.
Taylor-Robinson D; Schorlemmer HU; Furr PM; Allison AC
Clin Exp Immunol; 1978 Sep; 33(3):486-94. PubMed ID: 367651
[TBL] [Abstract][Full Text] [Related]
4. In vitro synthesis of factor B of the alternative pathway of complement activation by mouse peritoneal macrophages.
Bentley C; Bitter-Suermann D; Hadding U; Brade V
Eur J Immunol; 1976 Jun; 6(6):393-8. PubMed ID: 1033069
[TBL] [Abstract][Full Text] [Related]
5. Cytolytic mechanisms of activated macrophages. Tumor necrosis factor and L-arginine-dependent mechanisms act synergistically as the major cytolytic mechanisms of activated macrophages.
Higuchi M; Higashi N; Taki H; Osawa T
J Immunol; 1990 Feb; 144(4):1425-31. PubMed ID: 2303713
[TBL] [Abstract][Full Text] [Related]
6. The third component of complement (C3) bound to tumor target cells enhances their sensitivity to killing by activated macrophages.
Bara S; Lint TF
J Immunol; 1987 Feb; 138(4):1303-9. PubMed ID: 3100634
[TBL] [Abstract][Full Text] [Related]
7. Tumoricidal effector mechanisms of murine BCG-activated macrophages. I. Parameters of production and initial characterization of a cytolytic factor serologically related to necrosin.
Klostergaard J; Foster WA; Leroux ME
J Biol Response Mod; 1987 Jun; 6(3):313-30. PubMed ID: 3298554
[TBL] [Abstract][Full Text] [Related]
8. Tumor target-derived soluble factor synergizes with IFN-gamma and IL-2 to activate macrophages for tumor necrosis factor and nitric oxide production to mediate cytotoxicity of the same target.
Jiang H; Stewart CA; Fast DJ; Leu RW
J Immunol; 1992 Sep; 149(6):2137-46. PubMed ID: 1517576
[TBL] [Abstract][Full Text] [Related]
9. Complement regulation in murine and human hypercholesterolemia and role in the control of macrophage and smooth muscle cell proliferation.
Verdeguer F; Castro C; Kubicek M; Pla D; Vila-Caballer M; Vinué A; Civeira F; Pocoví M; Calvete JJ; Andrés V
Cardiovasc Res; 2007 Nov; 76(2):340-50. PubMed ID: 17673191
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of human complement by a C3-binding peptide isolated from a phage-displayed random peptide library.
Sahu A; Kay BK; Lambris JD
J Immunol; 1996 Jul; 157(2):884-91. PubMed ID: 8752942
[TBL] [Abstract][Full Text] [Related]
11. Evidence for the involvement of cytolytic macrophages in rejection of SV40-induced tumors.
Chapes SK; Gooding LR
J Immunol; 1985 Sep; 135(3):2192-8. PubMed ID: 2991384
[TBL] [Abstract][Full Text] [Related]
12. Interaction of soluble C3 fragments with guinea pig lymphocytes. Comparison of effects of C3a, C3b, C3c, and C3d on lymphokine production and lymphocyte proliferation.
Koopman WJ; Sandberg AL; Wahl SM; Mergenhagen SE
J Immunol; 1976 Jul; 117(1):331-6. PubMed ID: 932430
[TBL] [Abstract][Full Text] [Related]
13. Inactivation of C3a by a monocarboxypeptidase present in culture supernatants of stimulated guinea pig peritoneal macrophages.
Kreuzpaintner G; Damerau B; Zimmermann B; Plummer TH; Brade V
J Immunol; 1986 May; 136(9):3384-9. PubMed ID: 3485689
[TBL] [Abstract][Full Text] [Related]
14. A novel rat monoclonal antibody reactive with murine tumoricidal Kupffer cells and activated peritoneal macrophages from BCG-infected mice.
Someya A
Immunology; 1986 Apr; 57(4):605-10. PubMed ID: 2420709
[TBL] [Abstract][Full Text] [Related]
15. Anti-KCA-3, a monoclonal antibody reactive with a rat complement C3 receptor, distinguishes Kupffer cells from other macrophages.
Maruiwa M; Mizoguchi A; Russell GJ; Narula N; Stronska M; Mizoguchi E; Rabb H; Arnaout MA; Bhan AK
J Immunol; 1993 May; 150(9):4019-30. PubMed ID: 8473747
[TBL] [Abstract][Full Text] [Related]
16. Induction of thromboxane release from macrophages by anaphylatoxic peptide C3a of complement and synthetic hexapeptide C3a 72-77.
Hartung HP; Bitter-Suermann D; Hadding U
J Immunol; 1983 Mar; 130(3):1345-9. PubMed ID: 6600482
[TBL] [Abstract][Full Text] [Related]
17. In vitro and in vivo augmentation by muroctasin of the production of the third component of complement by murine macrophages.
Endo N
Arzneimittelforschung; 1988 Jul; 38(7A):993-6. PubMed ID: 3190805
[TBL] [Abstract][Full Text] [Related]
18. Mechanisms of target recognition and destruction in macrophage-mediated tumor cytotoxicity.
Adams DO; Johnson WJ; Marino PA
Fed Proc; 1982 Apr; 41(6):2212-21. PubMed ID: 6804274
[TBL] [Abstract][Full Text] [Related]
19. Expression of Ia antigens on macrophages is reduced after stimulation with homologous C3b.
Mauer U; Burger R; von Steldern D; Bitter-Suermann D; Hadding U
J Immunol; 1984 Jun; 132(6):2802-6. PubMed ID: 6586832
[TBL] [Abstract][Full Text] [Related]
20. Macrophage tumor cell interaction is enhanced by C3 fragments.
Lipari M; di Renzo L; Zicari A; Serarcangeli S; Huemer HP; Larcher C; Dierich MP; Pontieri G
Immunobiology; 1991 Nov; 183(5):363-73. PubMed ID: 1786985
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
